Cantuzumab mertansine
Based on 1 Customer Validation
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792)) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.02%
- CAS No.: 400010-39-1
- Masse moléculaire:150000 (average)
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-P9985
Disitamab vedotin -
HY-P3239
Belantamab mafodotin -
HY-141601
Telisotuzumab vedotin -
HY-P99813
Patritumab deruxtecan -
HY-P99107A
Brentuximab vedotin (solution) -
HY-109539
Gemtuzumab ozogamicin -
HY-152963
Tisotumab vedotin -
HY-132253
Polatuzumab vedotin -
HY-P99349
Loncastuximab tesirine -
HY-P99681
Labetuzumab govitecan -
HY-P99683
Ladiratuzumab vedotin -
HY-141606
Anetumab ravtansine
Activité biologique
Description
In Vitro
Cantuzumab mertansine (SB-408075; huC242-DM1; 0-100 μM; 24 h) has selective cytotoxic activity on antigen-positive COLO 205 cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Antigen-positive COLO 205 cell line and the antigen-negative A-375 melanoma cell line
-
Concentration:0-100 μM
-
Incubation Time:24 h
-
Result:Had cytotoxic activity on COLO 205 cells with an IC50 value of 0.032 nM (23.5 pg/ml).
Had 1100-fold less cytotoxic activity for the antigen-negative A-375 cells (IC50=36 nM; 26.5 ng/ml).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female CB-17 SCID mice, 6-7 weeks of age bearing COLO 205 human colon tumor xenografts[1]
-
Dosage:300 μg/kg
-
Administration:Daily for 5 days
-
Result:Completely eliminated any measurable tumors within 2 weeks of the initiation of therapy, and all eight animals were tumor-free for 200 days (duration of the experiment).
Chemical Information
-
CAS No. 400010-39-1
-
Appearance Liquid
-
Masse moléculaire 150000 (average)
-
Color Colorless to light yellow
-
SMILES
[Cantuzumab mertansine]
-
Synonyms
SB-408075; huC242-DM1
-
Livraison
Shipping with dry ice.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Paul R Helft, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 1;10(13):4363-8. [Content Brief]
[2]. Anthony W. Tolcher, et al. Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. J Clin Oncol. 2003 Jan 15;21(2):211-22. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Cantuzumab mertansine Related Classifications
HY-P99492 Related Classifications
Powered by Bioz